Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
3
50%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 21 (16.7%)
Phase 33 (50.0%)

Trials by Status

completed583%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_3

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

NCT05621070
completedphase_1

A Pharmacokinetic Study of JS002 in Healthy Subjects

NCT05859529
completedphase_2

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

NCT04515927
completedphase_3

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

NCT04781114
completedphase_3

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

NCT05532800
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05621070Phase 3

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Recruiting
NCT05859529Phase 1

A Pharmacokinetic Study of JS002 in Healthy Subjects

Completed
NCT04515927Phase 2

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Completed
NCT04781114Phase 3

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Completed
NCT05532800Phase 3

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Completed
NCT04197817Phase 1

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6